MedTech

US Droplet – Sonophoresis

Drug DeliverySonophoresisUltrasound

Ultrasound-triggered release of active ingredients contained within a hydrogel or a double-emulsion

Download the technology sheet

Ref. No.: MA00665

Summary

Karim Ghoufiri

Business Developer

Ce contenu est disponible en français

Technology

  • Microfluidic encapsulation process of active ingredients in liposomes for their controlled differential release in time and space using ultrasound: the vesicles can be opened and then reclosed when the pulse stops.
  • These vectors can be administered intravenously or incorporated into a hydrogel for topical application.
  • The carrier may consist of a double emulsion, either hydrophilic and/or hydrophobic.
  • Low-frequency ultrasound is used, featuring an innovative mechanism that destabilizes the electrostatic interactions within the hydrogel network.
  • No cavitation or overheating occurs, which could otherwise damage tissues.

 

Market

  • Two versions: for topical use (patch or dressing) and for intravenous use.
  • Active ingredients: growth factors, antibiotics, drugs, hyaluronic acid, etc.
  • Potential applications: rheumatology, dermatology, oncology, cosmetics, diabetology, physiotherapy.

 

Development status

  • US Droplet : encapsulation of fluorescent probes in double emulsions subjected to ultrasound treatment (7 min, duty cycles 5–50%) shows that molecule release increases proportionally with treatment intensity
  • Sonophoresis: encapsulation of BSA in alginate gels treated with focused ultrasound (5%, 20–60 min) results in protein release correlated with exposure time, despite only ~2% of the volume being directly exposed.

 

IP

  • Patent application filed on December 16, 2022 (WO2024/126605) – CN, KR, US, JP, EP.
  • Patent application filed on June 21, 2021 (WO2022/268284) – US, EP.

 

Valorisation strategy

  • Licensing